Amgen Inc
NASDAQ:AMGN
Amgen Inc
NASDAQ:AMGN
Price:
375.43
USD
-0.41%
Market Closed
Market Cap:
$202.2B
Relative Value
The Relative Value of one
AMGN
stock under the Base Case scenario is
403.58
USD.
Compared to the current market price of 375.43 USD,
Amgen Inc
is
Undervalued by 7%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AMGN
Relative Value
Base Case
403.58
USD
Undervaluation 7%
Multiples Across Competitors
AMGN Competitors Multiples
Amgen Inc Competitors
Amgen Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD | 5.5 | 26.2 | 15 | 15 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
401.3B USD | 6.6 | 95.9 | 15.7 | 21.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.4B USD | 6.3 | 21.7 | 13.5 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126.8B USD | 10.6 | 32.1 | 24.3 | 25.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.6B USD | 5.7 | 18.1 | 13.6 | 15.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.7B AUD | 3.2 | 34.9 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.1B EUR | 11.2 | 35.8 | 39 | 39.8 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
42.7B USD | 11.5 | 136.2 | 75.9 | 84.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
